老年难治性抑郁:增效与换药疗效的调节因素
该研究对OPTIMUM随机对照试验(N=742)进行预设调节分析,对象为60岁及以上难治性抑郁患者。结果显示,既往足量抗抑郁药试验次数是抑郁症状改善的显著调节因素(b=-1.6,P=0.033),仅既往试验少于3次的患者中增效优于换药,其他候选调节因素均不显著。
要点
- 既往足量抗抑郁药试验次数可调节增效与换药的疗效差异。
- 仅既往试验少于3次的老年患者中,增效策略优于换药。
- 年龄、执行功能障碍、躯体共病、焦虑共病均未显示显著调节作用。
核心结论
- 仅在既往抗抑郁药足量试验少于3次的老年难治性抑郁患者中,增效治疗优于换药。
- 既往足量抗抑郁药试验次数是抑郁症状改善的显著调节因素,其他候选调节因素不显著。
研究设计与样本
- 对OPTIMUM随机对照试验(N=742)进行预设调节分析,纳入60岁及以上难治性抑郁患者。
- 参与者随机接受阿立哌唑(2.5-15 mg)、安非他酮(150-450 mg)或锂盐(目标血清浓度0.6 mmol/L)增效,或换用安非他酮(150-450 mg)或去甲替林(目标血清浓度80-120 ng/mL),疗程10周。
主要发现
- 既往足量抗抑郁药试验次数显著调节抑郁症状改善(b=-1.6,t=-2.1,P=0.033,95% CI [-3.0, -0.1])。
- 该调节效应在所有增效策略中相似。
- 年龄、执行功能障碍、躯体共病、焦虑共病等其他候选调节因素均不显著。
关键数值与推荐
- 症状改善定义为蒙哥马利-阿斯伯格抑郁评定量表(MADRS)评分从基线至第10周的变化。
- 缓解定义为第10周MADRS评分≤10。
- 既往足量抗抑郁药试验次数调节症状改善的系数b=-1.6,t=-2.1,P=0.033,95% CI [-3.0, -0.1]。
临床怎么用
- 对既往抗抑郁药足量试验少于3次的老年难治性抑郁患者,可优先考虑增效治疗而非换药。
- 对既往足量试验达3次及以上的老年患者,应考虑其他干预策略而非单纯增效或换药。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Older adults with treatment-resistant depression (TRD) benefit more from treatment augmentation than switching. It is useful to identify moderators that influence these treatment strategies for personalised medicine. AIMS: Our objective was to test whether age, executive dysfunction, comorbid medical burden, comorbid anxiety or the number of previous adequate antidepressant trials could moderate the superiority of augmentation over switching. A significant moderator would influence the differential effect of augmentation versus switching on treatment outcomes. METHOD: We performed a preplanned moderation analysis of data from the Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM) randomised controlled trial (N = 742). Participants were 60 years old or older with TRD. Participants were either (a) randomised to antidepressant augmentation with aripiprazole (2.5-15 mg), bupropion (150-450 mg) or lithium (target serum drug level 0.6 mmol/L) or (b) switched to bupropion (150-450 mg) or nortriptyline (target serum drug level 80-120 ng/mL). Treatment duration was 10 weeks. The two main outcomes of this analysis were (a) symptom improvement, defined as change in Montgomery-Asberg Depression Rating Scale (MADRS) scores from baseline to week 10 and (b) remission, defined as MADRS score of 10 or less at week 10. RESULTS: Of the 742 participants, 480 were randomised to augmentation and 262 to switching. The number of adequate previous antidepressant trials was a significant moderator of depression symptom improvement (b = -1.6, t = -2.1, P = 0.033, 95% CI [-3.0, -0.1], where b is the coefficient of the relationship (i.e. effect size), and t is the t-statistic for that coefficient associated with the P-value). The effect was similar across all augmentation strategies. No other putative moderators were significant. CONCLUSIONS: Augmenting was superior to switching antidepressants only in older patients with fewer than three previous antidepressant trials. This suggests that other intervention strategies should be considered following three or more trials.
引用
- Kim HK, Karp JF, Lavretsky H, et al. Moderators of antidepressant augmentation versus switch in the OPTIMUM randomised controlled trial. Br J Psychiatry. 2025. PMID: 40534411. doi:10.1192/bjp.2025.125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。